US-based gene-engineering technology developer Inscripta has received $30m in series C funding from existing investors including Mérieux Développement, the strategic investment arm of medical technology producer Institut Mérieux.
The company had raised $55.5m March this year for the round’s first tranche, which was co-led by Mérieux Développement and investment firm Paladin Capital Group and backed by Venrock, Foresite, MLS Capital and NanoDimension.
Inscripta is working on a range of gene-editing technology that includes Crispr enzymes, nucleases and tools such as dedicated instruments and software. It revealed the latest funding roughly a year after the commercial release of its MAD7 enzyme.
Kevin Ness, Inscripta’s chief executive, said: “The next step is for Inscripta to offer biotech innovators a suite of new technology tools to enable forward cell-engineering in a way never before possible.
“Impressed with our progress, our current investors decided to double down and make an investment that will quicken our ability to bring these tools to market.”
Inscripta had raised $6m in series A capital from NanoDimension and MLS in 2016 before Venrock led the company’s $23m series B round in February 2017, participating alongside Foresite, Paladin Capital, NanoDimension and MLS.